Abstract 1567P
Background
The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of gastric cancer remains unknown. This study aims to compare the effects of SGLT2I and DPP4I on gastric cancer and other gastric diseases.
Methods
This was a retrospective population-based cohort study of patients with type-2 diabetes mellitus (T2DM) on either SGLT2I or DPP4I between 1st January 2015 and 31st December 2020 in Hong Kong. The primary outcome was new-onset gastric cancer, peptic ulcer (PU), acute gastritis, non-acute gastritis, and gastroesophageal reflux disease (GERD). Propensity score matching (1:1 ratio) using the nearest neighbour search was performed. Univariable and multivariable Cox regression was applied to identify the associations.
Results
This cohort included 62858 T2DM patients (median age: 62.2 years old [SD: 12.8]; 55.93% males). 23442 patients used SGLT2I, and 39416 patients used DPP4I. After matching, the incidence of gastric cancer (incidence rate ratio, IRR: 0.26; 95% confidence interval, CI: 0.18-0.37) was significantly lower in SGLT2I users than in DPP4I. SGLT2I was associated with lower risks of gastric cancer (Hazard ratio, HR: 0.30; 95% CI: 0.19-0.48). SGLT2I was also associated with lower risks of PU (HR: 0.66; 95% CI: 0.47-0.91), acute gastritis (HR: 0.31; 95% CI: 0.20-0.48), non-acute gastritis (HR: 0.35; 95% CI: 0.25-0.49), and GERD (HR: 0.62; 95% CI: 0.50-0.76) compared to DPP4I after adjustments. In the subgroup analysis, the results remained consistent across different age groups and genders. SGLT2I was associated with lower risks of gastric cancer amongst patients without prior H. pylori infection (HR: 0.26; 95% CI: 0.18-0.37) but not those with prior infection (HR: 0.28; 95% CI: 0.08-1.01). The results were consistent in the competing risk models and the different matching approaches in the sensitivity analysis.
Conclusions
SGLT2I was associated with lower risks of new-onset gastric cancer than DPP4I. SGLT2I was also associated with lower risks of PU, acute gastritis, non-acute gastritis, and GERD after matching and adjustments compared to DPP4I.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cardiovascular Analytics Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1498P - HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC
Presenter: Assya Akli
Session: Poster session 21
1499P - Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Etienne Giroux-Leprieur
Session: Poster session 21
1500TiP - REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Presenter: Ehsan Ghorani
Session: Poster session 21
1502TiP - A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1
Presenter: Fiona Blackhall
Session: Poster session 21
1503TiP - A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Presenter: Mark Awad
Session: Poster session 21
1504TiP - HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment
Presenter: WenFeng Fang
Session: Poster session 21
1505TiP - TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
Presenter: Isamu Okamoto
Session: Poster session 21
1506TiP - A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)
Presenter: William Nassib William Junior
Session: Poster session 21
1507TiP - Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
Presenter: David Planchard
Session: Poster session 21